Amarin calls on Banner, Catalent, Chemport and Equateq for AMR101 supply

Related tags Pharmacology

Amarin has turned to CMOs to support the commercial launch of its prescription grade omega-3 fatty acid drug AMR101 for high triglyceride levels.

Under the contracts Catalent Pharma Solutions and Banner Pharmacaps Europe, the latter of which worked with Amarin on AMR101’s clinical development, will provide softgel encapsulation services.

In addition, UK based Equateq and South Korea’s Chemport will join an existing unnamed firm as suppliers of the drug’s active pharmaceutical ingredient (API).

Amarin CEO Joseph Zakrzewski said: "A primary 2011 goal for Amarin is to expand our global supply chain to support expected product demand, diversify our supply base and ensure cost-efficient supply.

“We believe that the addition of these suppliers position us, subject to regulatory approval, for an aggressive launch of AMR101​."

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars